CellNovation Technology

CellNovation is a South Korean biotechnology company specializing in the development of next-generation cell therapies for the treatment of solid tumors. The company leverages its proprietary platform to enhance the efficacy and infiltration of immune cells, such as Natural Killer (NK) cells, into the tumor microenvironment. By focusing on cell-to-cell and cell-to-matrix interactions, CellNovation aims to overcome the limitations of current CAR-T and CAR-NK therapies in treating complex cancers. Their pipeline includes several preclinical programs targeting various solid tumor indications, including gastric and pancreatic cancers. The company is backed by prominent Korean venture capital firms and is actively advancing its lead candidates toward clinical trials.